Georgian company Novatec International and the leading Israeli medical-technological company Elsmed Healthcare Solutions together with the Belgian company IBA (Ion Beam Applications S.A.), are launching the setting-up of a radiopharmaceutical production facility in Tbilisi, Georgia.

The first of its kind project in Georgia will be located in Tbilisi and will include the construction of an ultra-modern radiopharmaceutical facility equipped with the latest technologies. The center will produce various types of radiopharmaceuticals.

The design, construction, operation, and production processes of the facility will be compliant with the International Atomic Energy Agency (IAEA) standards but also in line with the recommendations of the world leader Belgian equipment manufacturing company IBA, and the requirements defined by the Georgian legislation.

“Nowadays, radiopharmacies need to produce an increasing amount of FDG in a limited time and to produce numerous other compounds the same day. The Cyclone® KIUBE is the perfect solution with its ability to produce the widest range of radioisotopes and covers all the needs of PET radiopharmacies”, said Bruno Scutnaire, President at IBA RadioPharma Solutions.

The General Director of Novatec International, Giorgi Glonti, stated that the negotiations between the parties were successfully completed and relevant agreements were already signed and enabling the project start-up for the setting-up of a state-of-the-art radiopharmaceutical production facility in Georgia. According to Mr. Glonti, the project is unique and on-site production of radiopharmaceutical compounds will significantly boost the development of nuclear medicine in the Country. This initiative will also contribute to increase the availability of Positron-Emission Computed Tomography (PET-CT) for the population and therefore enhance oncology diagnosis for a more accurate treatment plan. Novatec International's radiopharmaceutical facility will be able to fully cover the current and future demand of the Georgian market, both in terms of production and delivery of fluorodeoxyglucose (¹⁸F-FDG) as well as other radioactive isotopes, including other fluorine-based isotopes.

The General Manager of the Israeli company Elsmed Healthcare Solutions, Hen Lederman states that the company is pleased to participate in such unique and useful project. According to Mr. Lederman, the joined efforts of Elsmed Healthcare Solutions and IBA will have a significant, positive effect in the fight against cancer in Georgia. The Israeli side will be additionally involved in the facility design, operation team training in cooperation with leading nuclear medicine centers in Israel and will provide continuous support to the project completion.

Novatec International plans to open this radiopharmaceutical production facility in 2024.

About Elsmed

Elsmed Healthcare Solutions Ltd is a leading well-known company providing turnkey solutions including establishment of complete medical centers worldwide as well as oncology centers and other various ventures in the medical field with international standards. The essence of the company’s operations is to provide the latest and most advanced medical services to populations worldwide with an active involvement.

The company’s main activities are focused on establishing, managing and maintaining turnkey medical projects starting from the development stage through the planning, building, procurement, technical and medical training as well as routine operations and mainly after sale ongoing service support.

Elsmed Healthcare Solution has assembled the best and most qualified professionals in all disciplines: consultants, architects, engineers, project managers, financial experts, technologists and medical technicians, physicians, proving track record in the establishment of medical projects internationally. For more information please visit:

www.elsmed-healthcare.com

About IBA

IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

(Ad)